Exclusive partnership results in a user-centric, hydrocarbon-cooled centrifuge purpose-built for clinical trials - years ahead of upcoming F-gas regulatory changes in Europe and the U.S.

LEESBURG, Va. and QINGDAO, China, Oct. 7, 2026 /PRNewswire/ -- Resonant Clinical Solutions - a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle - and Haier Biomedical - a trusted leader in reliable and sustainable laboratory equipment - have launched an innovative benchtop centrifuge using a natural refrigerant. The hydrocarbon-cooled LX-60T100R is specifically designed for clinical trials use, with new features that reduce its environmental impact and overcome constraints that have previously limited equipment in this category. The reengineered centrifuge is the result of an ongoing partnership between the two companies.

The strategic collaboration combined Haier Biomedical's engineering expertise with Resonant's clinical trials knowledge to create a modern, user-centric instrument. Importantly, the centrifuge complies with upcoming legislation further restricting the use of fluorinated greenhouse gases (F-gases) - historically used as refrigerants in laboratory instruments - due to their significant global warming potential (GWP). The jointly developed centrifuge directly addresses this challenge, and is available more than two years ahead of critical industry deadlines in Europe and the U.S.

The LX-60T100R meets the demanding needs of pharmaceutical sponsors and contract research organizations (CROs), helping them to prepare for upcoming regulation changes and deliver on corporate environmental sustainability commitments while enhancing safety, reliability, and ease of use.

Key features of the LX-60T100R include:

Natural hydrocarbon (R290) refrigerant, substantially lowering environmental impact compared to legacy F-gas systems
Rapid pre-cooling from room temperature to 4 °C in approximately five minutes, reducing the wait times associated with legacy refrigerated centrifuges
Speed and rotor profile matched to routine clinical trial workflows, such as blood collection tubes, 15 and 50 mL conical flasks, and bottles up to 100 mL
Advanced 7-inch LCD touchscreen with multi-point touch control that is responsive even with gloves, on-screen calibration and configuration, RFID rotor recognition, user log-in controls, and storage for over 1,000 programs
Built-in safety and reliability monitoring, with vibration and imbalance detection, level check, rotor-life tracking and warning, and an ultra-low center of gravity that limits vibration
Quiet, lab-friendly operation, as low as 52 dB(A) in fixed-angle rotor configurations, suited to shared lab environments and long processing runs
Weighs ~46 kg and fits on a standard laboratory bench without special floor mounting, reinforced surfaces or dedicated space
Significantly reduces refrigerant GWP from more than 1,400 in legacy F-gas systems to approximately 3,* without compromising cooling performance

Christophe Berthoux, Chief Executive Officer at Resonant Clinical Solutions, said: "We are laser-focused on providing world-class, customer-centric solutions that support the full lifecycle of complex clinical trial programs. Our collaboration with Haier Biomedical on this reimagined natural-refrigerant centrifuge has been pivotal in delivering innovative, globally supported technology that meets F-gas regulatory requirements and market demand, years ahead of mandated deadlines. Clinical trial centrifugation workflows will be easier, more flexible, and more environmentally sustainable with this industry-leading instrument."

Haier Biomedical's Co-Chief Executive Officer, Gang Liu, added: "Our ability to turn a concept into an innovative product in such a short period really shows our commitment to supporting our customers. Fresh challenges will continue to emerge across the biomedical sector, and we remain dedicated to working alongside scientists to develop novel solutions that help the industry move forward at pace. In this instance, the partnership with Resonant resulted in a modern, easy-to-use, and regulatory-compliant centrifuge that significantly enhances workflows while reducing the use of harmful greenhouse gases."

Clinical trial sponsors and CROs can purchase or rent the LX-60T100R refrigerated centrifuge exclusively from Resonant** through November 2027. The 220-240 V AC, 50/60 Hz model is immediately available for purchase or rental, with the 110 V AC, 50/60 Hz model launching in Q1 2027. More information can be obtained at resonantclinical.com/products/centrifuges.

* GWP measures a gas's climate impact relative to CO₂, which has a GWP of 1. A GWP of 1,000 therefore has around 1,000 times the warming impact of CO₂, while a GWP of 3 has around three times the impact.
** Exclusivity agreement covers the clinical trials market worldwide, excluding China.

About Resonant Clinical Solutions
Resonant Clinical Solutions is a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle. Through its Biorepository, Kitting, and Equipment & Ancillaries businesses, Resonant helps customers manage complexity, reduce risk, and support critical clinical programs around the world. With more than 850 employees across the U.S., U.K., and Europe, Resonant manages more than 100 million research assets in storage, and has supported more than 2,500 clinical trials and facilitated more than 20,000 customer-site shipments. The company serves pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and diagnostic and reference laboratories.

Resonant's mission is to empower its partners with comprehensive, global clinical supply chain and sample lifecycle solutions that remove complexity and enable them to focus on science and patients. For more information, visit resonantclinical.com.

About Haier Biomedical
Haier Biomedical is a global life sciences and medical technology company developing intelligent, connected and sustainable solutions for healthcare, research and public health. Established in 2005 and listed on the Shanghai Stock Exchange STAR Market, the company operates across more than 160 countries and regions through a global network spanning research, user experience, marketing, logistics, technical training and more than 800 distribution partners. From biobanking and smart laboratories to pharmacy, blood management and public health, Haier Biomedical combines technological innovation with close collaboration with customers, partners and end users. This combination of global capabilities and local-market insights enables the company to turn real-world needs into practical solutions that improve efficiency, resilience and outcomes across the life sciences and healthcare ecosystems.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/resonant-clinical-solutions-and-haier-biomedical-introduce-an-innovative-benchtop-centrifuge-with-a-natural-refrigerant-302900397.html

Images

Tags

More Like This

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion

"In Europe, For Europe": Haier Biomedical Spotlights Full-Scenario Lab Solutions at analytica Munich 2026

Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025

Haier Biomedical Hosts European Partner Summit in Rome and Advances "In Europe, for Europe" Strategy

Haier Biomedical Publishes 2025 Sustainability Report: Committed to Building a Platform for Technology, Industry and Social Responsibility

Resonant Clinical Solutions Expands Global Equipment & Ancillaries Business with Acquisition of Labfish

Resonant Clinical Solutions Expands Advanced-Therapy and Cryogenic Storage Capabilities with Acquisition of Creapharm Bioservices

Midea Highlights R290 Leadership and Sustainable HVAC Innovations at IFA 2026